Applications, hearings, determinations, etc.: Aldrich Chemical Co., Inc.,

Text

---

Federal Register: July 5, 2007 (Volume 72, Number 128)NoticesPage 36727-36728From the Federal Register Online via GPO Access [wais.access.gpo.gov]

DOCID:fr05jy07-108

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled Substances; Notice of Application

Pursuant to Sec. 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on May 18, 2007, Aldrich Chemical Company, Inc., DBA Isotec, 3858 Benner Road, Miamisburg, Ohio 45342-4304, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic class of controlled substance listed in schedule I and II:

Drug

Schedule

Cathinone (1235)........................... I Methcathinone (1237)....................... I N-Ethylamphetamine (1475).................. I N,N-Dimethylamphetamine (1480)............. I Aminorex (1585)............................ I Gamma Hydroxybutyric Acid (2010)........... I Methaqualone (2565)........................ I Ibogaine (7260)............................ I Lysergic acid dethylamide (7315)........... I Tetrahydrocannabinols (7370)............... I Mescaline (7381)........................... I 2,5-Dimethoxyamphetamine (7396)............ I 3,4-Methylenedioxyamphetamine (7400)....... I 3,4-Methylenedioxy-N-ethylamphetamine

I (7404). 3,4-Methylenedioxymethamphetamine (7405)... I 4-Methoxyamphetamine (7411)................ I Psilocybin (7437).......................... I Psilocyn (7438)............................ I N-Ethyl-1-phenylcyclohexylamine (7455)..... I Dihydromorphine (9145)..................... I Normorphine (9313)......................... I Acetylmethadol (9601)...................... I Alphacetylmethadol except levo-

I alphacetylmethadol (9603). Normethadone (9635)........................ I Norpipanone (9636)......................... I 3-Methylfentanyl (9813).................... I Amphetamine (1100)......................... II Methamphetamine (1105)..................... II Methylphenidate (1724)..................... II Amobarbital (2125)......................... II Pentobarbital (2270)....................... II Secobarbital (2315)........................ II 1-Phenylcyclohexylamine (7460)............. II Phencyclidine (7471)....................... II Phenylacetone (8501)....................... II 1-Piperidinocyclohexanecarbonitrile (8603). II Cocaine (9041)............................. II Codeine (9050)............................. II Dihydrocodeine (9120)...................... II Oxycodone (9143)........................... II Hydromorphone (9150)....................... II Benzoylecgonine (9180)..................... II Ethylmorphine (9190)....................... II Hydrocodone (9193)......................... II Isomethadone (9226)........................ II Meperidine (9230).......................... II Meperidine intermediate-A (9232)........... II Merperidine intermediate-B (9233).......... II Methadone (9250)........................... II Methadone intermediate (9254).............. II Dextropropoxyphene,bulk, (non-dosageforms) II (9273). Morphine (9300)............................ II Normorphine (9313)......................... II Thebaine (9333)............................ II Levo-alphacetylmethadol (9648)............. II Oxymorphone (9652)......................... II Fentanyl (9801)............................ II

The company plans to manufacture small quantities of the listed controlled substances to produce isotope labeled standards for drug testing and analysis.

Any other such applicant and any person who is presently registered with

[Page 36728]DEA to manufacture such a substance may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).

Any such written comments or objections being sent via regular mail should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), Washington, D.C. 20537, or any being sent via express mail should be sent to Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 2401 Jefferson Davis Highway, Alexandria, Virginia 22301; and must be filed no later than September 4, 2007.

Dated: June 26, 2007. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

FR Doc. E7-12976 Filed 7-3-07; 8:45 amBILLING CODE 4410-09-P

---